Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M. Schettini F, et al. Among authors: villarreal garza c. Cancer. 2024 Aug 15;130(16):2746-2762. doi: 10.1002/cncr.35323. Epub 2024 May 16. Cancer. 2024. PMID: 38752572 Free article.
Information Needs and Internet Use of Breast Cancer Survivors in Mexico.
Villarreal-Garza C, Platas A, Martinez-Cannon BA, Bargalló-Rocha E, Aguilar-González CN, Ortega-Leonard V, Ramos-Elías P, Hidalgo-Carrera J, Soto-Perez-de-Celis E. Villarreal-Garza C, et al. Breast J. 2017 May;23(3):373-375. doi: 10.1111/tbj.12747. Epub 2016 Dec 10. Breast J. 2017. PMID: 27943486 No abstract available.
HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever.
LaFleur C, Granados J, Vargas-Alarcon G, Ruíz-Morales J, Villarreal-Garza C, Higuera L, Hernández-Pacheco G, Cutiño-Moguel T, Rangel H, Figueroa R, Acosta M, Lazcano E, Ramos C. LaFleur C, et al. Hum Immunol. 2002 Nov;63(11):1039-44. doi: 10.1016/s0198-8859(02)00682-1. Hum Immunol. 2002. PMID: 12392857
HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis.
García-Ramos G, Téllez-Zenteno JF, Zapata-Zúñiga M, Yamamoto-Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, Vargas-Alarcón G, Estañol B, Llorente L, Granados J. García-Ramos G, et al. Eur J Neurol. 2003 Nov;10(6):707-10. doi: 10.1046/j.1468-1331.2003.00686.x. Eur J Neurol. 2003. PMID: 14641517 Clinical Trial.
Planning cancer control in Latin America and the Caribbean.
Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Goss PE, et al. Lancet Oncol. 2013 Apr;14(5):391-436. doi: 10.1016/S1470-2045(13)70048-2. Lancet Oncol. 2013. PMID: 23628188
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Arrieta O, Villarreal-Garza C, Pachuca D, Michel Ortega RM, Martinez-Barrera L, Flores-Estrada D, Astorga A. Arrieta O, et al. Med Oncol. 2011 Mar;28(1):300-6. doi: 10.1007/s12032-009-9401-y. Epub 2010 Jan 5. Med Oncol. 2011. PMID: 20049560
161 results